A method for reducing skin sensitization of an asenapine-containing patch comprising a backing layer and an adhesive agent layer, the method comprising: using an adhesive agent for preparing the adhesive agent layer, the adhesive agent containing free asenapine in a range of 2 to 5% by mass, styrene-isoprene-styrene block copolymer (SIS) in a range of 7 to 18% by mass, polyisobutylene (PIB) in a range of 0.5 to 10% by mass, alicyclic saturated hydrocarbon resin in a range of 30 to 70% by mass, and liquid paraffin in a range of 5 to 10% by mass, relative to a total amount of the adhesive agent; and preparing the asenapine-containing patch whose average cumulative amount of skin permeation of asenapine (24 hours) after applying the asenapine-containing patch to skin of a dorsal scapular region of a 5-week-old Hartley white female guinea pig and holding the asenapine-containing patch with an occlusive dressing for 24 hours is in a range of 90 to 300 μg/cm.sup.2 in terms of free form.

There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

Disclosed is a patch for alleviating cancerous pain. The patch is provided with a support layer and an adhesive layer laminated on the support layer. The adhesive layer contains an adhesive base and 150-225 mg of diclofenac sodium. One patch is used by being attached once per day.

A transdermal therapeutic system containing rotigotine base in a self-adhesive layer structure. The system includes a backing layer, and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase having a composition including 75% to 100% of a polymer or a polymer mixture, and an inner phase that forms dispersed deposits in the outer phase. The inner phase includes rotigotine base and a polymer mixture of at least two hydrophilic polymers. The hydrophilic polymers are selected from the group of polyvinylpyrrolidones having a K-Value of at least 80, polyvinylpyrrolidones having a K-Value of less than 80, copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The polymer mixture in the inner phase is present in an amount sufficient so that it forms a solid solution with the rotigotine base.

The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

The present invention provides a patch for attaching to teeth or a surrounding part of teeth, and the patch can be easily removed by tooth brushing alone.

The present invention provides a patch for relieving lumbago, the patch comprising a backing and an adhesive layer laminated on the backing, wherein the adhesive layer comprises an adhesive base and 0.70 to 1.50 mg of diclofenac sodium per cm.sup.2 of application area, and the patch is used by applying the patch once a day to the chest region, the abdominal region, the dorsal region, the brachial region, or the femoral region of a human.

Disclosed is a patch for relieving cancer pain, the patch comprising a support layer, and an adhesive layer laminated on the support layer, wherein the adhesive layer contains an adhesive base and diclofenac sodium. The patch is applied once a day, and is used such that the dosage of the diclofenac sodium is 150-225 mg per dose.

A patch includes: a support; and an adhesive layer on the support. The adhesive layer includes blonanserin or a salt thereof, a thermoplastic elastomer, and a higher fatty acid ester.